Title : Harnessing photobiomodulation therapy for alzheimer’s disease: A novel approach to neurodegenerative treatment
Abstract:
Introduction: Alzheimer’s Disease (AD) remains one of the most challenging neurodegenerative disorders, with limited therapeutic options available to halt or reverse its progression. Photobiomodulation (PBM) therapy, a non-invasive treatment that utilizes specific wavelengths of light to modulate cellular function, has emerged as a promising intervention for neurodegenerative diseases. This study explores the potential of PBM in mitigating the pathological hallmarks of AD, including amyloid-beta (Ab) aggregation, tau hyperphosphorylation, and neuroinflammation.
Methods: We conducted a series of in vitro and in vivo experiments to evaluate the effects of PBM on neuronal health and cognitive function. In vitro studies utilized human neuroblastoma cells exposed to Ab oligomers, while in vivo studies employed transgenic mouse models of AD. PBM was administered at specific wavelengths (660 nm and 810 nm) and dosages, with outcomes assessed through behavioral tests, immunohistochemistry, and molecular analyses.
Results: Our findings demonstrate that PBM significantly reduces Ab plaque burden and tau pathology in AD mouse models. Additionally, PBM treatment led to a marked decrease in neuroinflammatory markers, such as IL-6 and TNF-α, and an increase in neurotrophic factors, including BDNF. Behavioral assessments revealed improved cognitive performance in PBM-treated mice, particularly in memory and learning tasks. In vitro studies corroborated these results, showing enhanced neuronal survival and reduced oxidative stress in PBM-treated cells.
Conclusion: These results suggest that PBM therapy holds significant potential as a non-pharmacological intervention for Alzheimer’s Disease. By targeting multiple pathological mechanisms, PBM offers a holistic approach to AD treatment, potentially slowing disease progression and improving quality of life for patients. Further clinical trials are warranted to validate these findings and optimize PBM protocols for human use.
Keywords: Photobiomodulation, Alzheimer’s Disease, Neurodegeneration, Amyloid-beta, Tau, Neuroinflammation
